Pathogenic variants in the BRCA 1 and BRCA2 genes: what is important for a practicing gynecologist to know

DOI

https://dx.doi.org/10.18565/aig.2022.11.52-59

Yureneva S.V., Averyanova M.V., Ashrafyan L.A., Yakushevskaya O.V., Buyanovskaya O.A.
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

The BRCA1 and BRCA2 genes encode amino acid sequences in the nuclear proteins that are involved in the regulation of DNA damage repair and cell division. Pathogenic variants in the BRCA1 and BRCA2 gene cause chromosomal instability and malignant transformation of cells in the breast, ovaries, and other organs. The lifetime cumulative risk for breast cancer (BC) is as much as 72% and the risk for ovarian cancer (OC) is as much as 64% for female carriers of a pathogenic variant in the BRCA1. The risk for BC and OC for those of this variant in the BRCA2 gene is 69 and 17%, respectively. To a lesser extent, the carriers of pathogenic variants in the BRCA genes are at increased risk for other malignant neoplasms, such as melanoma, endometrial, pancreatic, peritoneal, and prostate and colon cancers. The presence of pathogenic variants in the BRCA1 and BRCA2 genes in a patient largely determines the choice of treatment policy, as well as preventive measures. Studies have shown that population screening for pathogenic variants in the BRCA1 and BRCA2 genes is cost-effective and can be used as an effective strategy to reduce the risk of BC/OC.
Conclusion: A clear algorithm of actions should be elaborated to identify pathogenic variants in the BRCA1 and BRCA2 genes in individuals without a history of BC/OC, by taking into account the patient's age and plans for the implementation of reproductive function. There is a need for further investigations on the rehabilitation of patients after preventive surgery, including the safety of hormone replacement therapy, the adjustment of optimal doses, the design of drugs, and the determination of the duration of their use.

BRCA

hereditary breast and ovarian cancers

preventive surgery

hormone replacement therapy

Full text (in Russian)

Жукова Л.Г., Андреева Ю.Ю., Завалишина Л.Э., Закиряходжаев А.Д.,Королева И.А., Назаренко А.В., Палтуев Р.М., Пароконная А.А., Петровский А.В., Портной С.М., Семиглазов В.Ф., Семиглазова Т.Ю., Стенина М.Б., Степанова А.М., Трофимова О.П., Тюляндин С.А., Франк Г.А.,Фролова М.А., Шатова Ю.С., Невольских А.А., Иванов С.А., Хайлова Ж.В.,ГеворкянТ.Г. Рак молочной железы. Клинические рекомендации. Современная онкология. 2021; 23(1): 5-40. https://dx.doi.org/10.26442/18151434.2021.1.200823. [Zhukova L.G., Andreeva Iu.Iu., Zavalishina L.E.,Zakiriakhodzhaev A.D., Koroleva I.A. et al. Breast cancer. Clinical recommendations. Journal of Modern Oncology. 2021; 23(1): 5-40.(in Russian)]. https://dx.doi.org/10.26442/18151434.2021.1.200823.
Pal T., Permuth-Wey J., Betts J.A., Krischer J.P., Fiorica J., Arango H. et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104(12): 2807-16. https://dx.doi.org/10.1002/cncr.21536.
Kuchenbaecker K.B., Hopper J.L., Barnes D.R., Phillips K.A., Mooij T.M., Roos-Blom M.J. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017; 317(23): 2402-16.https://dx.doi.org/10.1001/jama.2017.7112.
Soenderstrup I.M.H., Laenkholm A.V., Jensen M.B., Eriksen J.O., Gerdes A.M., Hansen T.V.O. et al. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. Acta Oncol. 2018; 57(1): 95-101.https://dx.doi.org/10.1080/0284186X.2017.1398415.
Levy-Lahad E., Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br. J. Cancer. 2007; 96(1): 11-5. https://dx.doi.org/10.1038/sj.bjc.6603535.
Matanes E., Volodarsky-Perel A., Eisenberg N., Rottenstreich M., Yasmeen A., Mitric C. et al. Endometrial cancer in germline BRCA mutation carriers: A systematic review and meta-analysis. J. Minim. Invasive Gynecol. 2021; 28(5): 947-56. https://dx.doi.org/10.1016/j.jmig.2020.11.023.
Michaan N., Leshno M., Cohen Y., Safra T., Peleg-Hasson S., Laskov I., Grisaru D. Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis. Reprod. Biol. Endocrinol. 2021; 19(1): 153.https://dx.doi.org/10.1186/s12958-021-00827-9.
Бит-Сава Е.М. Белогурова М.Б. Наследственный рак молочной железы. Сибирский онкологический журнал. 2013; 1: 75-81. [Bit-Sava E.M., Belogurova М.B. Hereditary breast cancer. Siberian journal of oncology. 2013;(1):75-81. (in Russian)].
Mavaddat N., Peock S., Frost D., Ellis S., Platte R., Fineberg E. et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J. Natl. Cancer Inst. 2013; 105(11): 812-22.https://dx.doi.org/10.1093/jnci/djt095.
Daly M.B., Pilarski R., Berry M., Buys S.S., Farmer M., Friedman S. et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J. Natl. Compr. Canc. Netw. 2017; 15(1) :9-20.https://dx.doi.org/10.6004/jnccn.2017.0003.
Rosen M.N., Goodwin R.A., Vickers M.M. BRCA mutated pancreatic cancer: A change is coming. World J. Gastroenterol. 2021; 27(17): 1943-58.https://dx.doi.org/10.3748/wjg.v27.i17.1943.
Shiovitz S., Korde L.A. Genetics of breast cancer: a topic in evolution. Ann. Oncol. 2015; 26(7): 1291-9. https://dx.doi.org/10.1093/annonc/mdv022.
Donnelly L.S., Watson M., Moynihan C., Bancroft E., Evans D.G., Eeles R. et al. Reproductive decision-making in young female carriers of a BRCA mutation. Hum. Reprod. 2013; 28(4): 1006-12. https://dx.doi.org/10.1093/humrep/des441.
Widschwendter M., Rosenthal A.N., Philpott S., Rizzuto I., Fraser L., Hayward J. et al. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncol. 2013; 14(12): 1226-32. https://dx.doi.org/10.1016/S1470-2045(13)70448-0.
Daly M.B., Pilarski R., Yurgelun M.B., Berry M.P., Buys S.S., Dickson P. et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020. J. Natl. Compr. Canc. Netw. 2020; 18(4): 380-91. https://dx.doi.org/10.6004/jnccn.2020.0017.
Familial Breast Cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. London: National Institute for Health and Care Excellence; 2019.
Konstantinopoulos P.A., Norquist B., Lacchetti C., Armstrong D., Grisham R.,Goodfellow P.J. et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J. Clin. Oncol. 2020; 38(11): 1222-45.https://dx.doi.org/10.1200/JCO.19.02960.
Tung N.M., Boughey J.C., Pierce L.J., Robson M.E., Bedrosian I., Dietz J.R.et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J. Clin. Oncol. 2020; 38(18): 2080-106.https://dx.doi.org/10.1200/JCO.20.00299.
Hong Y.C., Liu H.M., Chen P.S., Chen Y.J., Lyou J.Y., Hu H.Y. et al. Hair follicle: a reliable source of recipient origin after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007; 40(9): 871-4. https://dx.doi.org/10.1038/sj.bmt.1705823.
Tran S.D., Pillemer S.R., Dutra A.,. Barrett A.J., Brownstein M.J., Key S. et al. Differentiation of human bone marrow-derived cells into buccal epithelial cells in vivo: a molecular analytical study. Lancet (London, England). 2003; 361(9363): 1084-8. https://dx.doi.org/10.1016/S0140-6736(03)12894-2.
Giordano S., Garrett-Mayer E., Mittal N., Smith K., Shulman L., Passaglia C. et al. Association of BRCA1 mutations with impaired ovarian reserve: connection between infertility and breast/ovarian cancer risk. J. Adolesc. Young Adult Oncol. 2016; 5(4): 337-43. https://dx.doi.org/10.1089/jayao.2016.0009.
Ben-Aharon I., Levi M., Margel D., Yerushalmi R., Rizel S., Perry S. et al. Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging? Oncotarget. 2018; 9(22): 15931-41. https://dx.doi.org/10.18632/oncotarget.24638.
Johnson L., Sammel M.D., Domchek S., Schanne A., Prewitt M., Gracia C. Antimüllerian hormone levels are lower in BRCA2 mutation carriers. Fertil. Steril. 2017; 107(5): 1256-65.e6. https://dx.doi.org/10.1016/j.fertnstert.2017.03.018.
Lambertini M., Goldrat O., Ferreira A.R., Dechene J., Azim H.A. Jr, Desir J. et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann. Oncol. 2018; 29(1): 237-43. https://dx.doi.org/10.1093/annonc/mdx639.
Grynberg M., Dagher Hayeck B., Papanikolaou E.G., Sifer C., Sermondade N., Sonigo C. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro. Hum. Reprod. 2019; 34(2): 374-9. https://dx.doi.org/10.1093/humrep/dey358.
Gunnala V., Fields J., Irani M., D'Angelo D., Xu K., Schattman G., Rosenwaks Z. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation. Fertil. Steril. 2019; 111(2): 363-71. https://dx.doi.org/10.1016/j.fertnstert.2018.10.014.
Practice Bulletin No 182: Hereditary breast and ovarian cancer syndrome. Obstet. Gynecol. 2017; 130(3): e110-26. https://dx.doi.org/10.1097/AOG.0000000000002296.
Chan J.L., Johnson L.N.C., Sammel M.D., DiGiovanni L., Voong C., Domchek S.M., Gracia C.R. Reproductive decision-making in women with BRCA1/2 mutations. J. Genet. Couns. 2017; 26(3): 594-603.https://dx.doi.org/10.1007/s10897-016-0035-x.
Gaba F., Goyal S., Marks D., Chandrasekaran D., Evans O., Robbani S. et al. Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study. J. Med. Genet. 2022; 59(2): 122-32. https://dx.doi.org/10.1136/jmedgenet-2020-107501.
Ethics Committee of the American Society for Reproductive Medicine. Planned oocyte cryopreservation for women seeking to preserve future reproductive potential: an Ethics Committee opinion. Fertil. Steril. 2018; 110(6): 1022-8. https://dx.doi.org/10.1016/j.fertnstert.2018.08.027.
Anderson R.A., Amant F., Braat D., D'Angelo A., Chuva de Sousa Lopes S.M., Demeestere I. et al. ESHRE guideline: female fertility preservation. Hum. Reprod. Open. 2020; 2020(4): hoaa052. https://dx.doi.org/10.1093/hropen/hoaa052.
Gaba F., Robbani S., Singh N., McCluggage W.G., Wilkinson N., Ganesan R. et al. Preventing Ovarian Cancer Through early excision of tubes and late ovarian removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial. Int. J. Gynecol. Cancer. 2021; 31(2): 286-91.https://dx.doi.org/10.1136/ijgc-2020-001541.
Gasparri M.L., Taghavi K., Fiacco E., Zuber V., Di Micco R., Gazzetta G. et al. Risk-reducing bilateral salpingo-oophorectomy for BRCA mutation carriers and hormonal replacement therapy: if it should rain, better a drizzle than a storm. Medicina (Kaunas). 2019; 55(8): 415. https://dx.doi.org/10.3390/medicina55080415.
Xiao Y.L., Wang K., Liu Q., Li J., Zhang X., Li H.Y. Risk reduction and survival benefit of risk-reducing salpingo-oophorectomy in hereditary breast cancer: Meta-analysis and systematic review. Clin. Breast Cancer. 2019; 19(1): e48-65. https://dx.doi.org/10.1016/j.clbc.2018.09.011.
Li X., You R., Wang X., Liu C., Xu Z., Zhou J. et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: A meta-analysis and systematic review. Clin. Cancer Res. 2016; 22(15): 3971-81.https://dx.doi.org/10.1158/1078-0432.CCR-15-1465.
Jacobson M., Narod S.A. Does oophorectomy reduce breast cancer mortality for BRCA mutation carriers after breast cancer? Expert Rev. Anticancer Ther. 2018; 18(4): 305-6. https://dx.doi.org/10.1080/14737140.2018.1438891.
Hunsinger V., Marchac A.C., Derder M., Hivelin M., Lecuru F., Bats A.S., Lantieri L. A new strategy for prophylactic surgery in BRCA women: Combined mastectomy and laparoscopic salpingo-oophorectomy with immediate reconstruction by double DIEP flap. Ann. Chir. Plast. Esthet. 2016; 61(3): 177-82. https://dx.doi.org/10.1016/j.anplas.2016.02.002.
Karnezis A.N., Cho K.R., Gilks C.B., Pearce C.L., Huntsman D.G. The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat. Rev. Cancer. 2017; 17(1): 65-74. https://dx.doi.org/ 10.1038/nrc.2016.113.
Kindelberger D.W., Lee Y., Miron A., Crum CP. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am. J. Surg. Pathol. 2007; 31(2): 161-9. https://dx.doi.org/10.1097/01.pas.0000213335.40358.47.
Tang S., Onuma K., Deb P., Wang E., Lytwyn A., Sur M., Daya D. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int. J. Gynecol. Pathol. 2012; 31(2): 103-10. https://dx.doi.org/10.1097/PGP.0b013e31822ea955.
van Lieshout L.A.M., Piek J.M.J., Verwijmeren K., Houterman S., Siebers A.G., de Hullu J.A., Bekkers R.L.M. Ovarian cancer risk after salpingectomy for ectopic pregnancy or hydrosalpinx: results of the OCASE nationwide population-based database study. Hum. Reprod. 2021; 36(1): 211-8. https://dx.doi.org/10.1093/humrep/deaa264.
Steenbeek M.P., Harmsen M.G., Hoogerbrugge N., de Jong M.A., Maas A.H.E.M., Prins J.B. et al. Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1/2 pathogenic variant carriers: a nonrandomized controlled trial. JAMA Oncol. 2021; 7(8): 1203-12. https://dx.doi.org/10.1001/jamaoncol.2021.1590.
Jacobson M.R., Walker M., Ene G.E.V., Firestone C., Bernardini M.Q., Allen L. et al. Factors affecting surgical decision-making in carriers of BRCA1/2 pathogenic variants undergoing risk-reducing surgery at a dedicated hereditary ovarian cancer clinic. Menopause. 2021; 29(2): 151-5. https://dx.doi.org/10.1097/GME.0000000000001900.
Gan C., Chenoy R., Chandrasekaran D., Brockbank E., Hollingworth A., Vimplis S. et al. Persistence of fimbrial tissue on the ovarian surface after salpingectomy. Am. J. Obstet. Gynecol. 2017; 217(4): 425.e1-425.e16.https://dx.doi.org/10.1016/j.ajog.2017.06.004.
Gazzuola Rocca L., Smith C.Y., Stewart E.A., Rocca W.A. Adverse childhood experiences and adult abuse are predictors of hysterectomy and oophorectomy. Maturitas. 2017; 106: 95-6. https://dx.doi.org/10.1016/j.maturitas.2017.08.001.
Siyam T., Ross S., Campbell S., Eurich D.T., Yuksel N. The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review. BMC Womens Health. 2017; 17(1): 22. https://dx.doi.org/10.1186/s12905-017-0370-6.
Reid R., Abramson B.L., Blake J., Desindes S., Dodin S., Johnston S. et al. Managing menopause. J. Obstet. Gynaecol. Can. 2014; 36(9): 830-3.https://dx.doi.org/10.1016/S1701-2163(15)30487-4.
Scientific Impact Paper No. 48: management of women with a genetic predisposition to gynaecological cancers. Obstet. Gynaecol. 2015; 17(2): 140. https://dx.doi.org/10.1111/tog.12182.
Armstrong D.K., Alvarez R.D., Bakkum-Gamez J.N., Barroilhet L., Behbakht K.et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(2): 191-226.https://dx.doi.org/10.6004/jnccn.2021. 0007.
Vermeulen R.F.M., Korse C.M., Kenter G.G., Brood-van Zanten M.M.A., van Beurden M. Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines. Climacteric. 2019; 22(4): 352-60. https://dx.doi.org/10.1080/13697137.2019.1582622.
Faubion S.S., Kuhle C.L., Shuster L.T., Rocca W.A. Long-term health consequences of premature or early menopause and considerations for management. Climacteric. 2015; 18(4): 483-91. https://dx.doi.org/10.3109/13697137.2015.1020484.
Faubion S.S., Files J.A., Rocca W.A. When lowest dose for shortest amount of time does not apply. J. Womens Health (Larchmt). 2016; 25(4): 416-7.https://dx.doi.org/10.1089/jwh.2016.5781.
Passaperuma K., Warner E., Causer P.A., Hill KA., Messner S., Wong J.W. et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br. J. Cancer. 2012; 107(1): 24-30. https://dx.doi.org/10.1038/bjc.2012.204.
Bevers T.B., Helvie M., Bonaccio E., Calhoun K.E., Daly M.B., Farrar W.B. et al. Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2018; 16(11): 1362-89. https://dx.doi.org/10.6004/jnccn.2018.0083.
London Cancer Alliance. LCA breast cancer clinical guidelines. October 2013 (updated March 2016).
Senkus E., Kyriakides S., Ohno S., Penault-Llorca F., Poortmans P., Rutgers E. et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015; 26(Suppl. 5): v8-30. https://dx.doi.org/10.1093/annonc/mdv298.
Runowicz C.D., Leach C.R., Henry N.L., Henry K.S., Mackey H.T., Cowens-Alvarado R.L. et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J. Clin. 2016; 66(1): 43-73. https://dx.doi.org/10.3322/caac.21319.
The Royal Gollege of Radiologists. Clinical Radiology. Guidance on screening and symptomatic breast imaging. Third edition.https://www.rcr.ac.uk
Metcalfe K., Eisen A., Senter L., Armel S., Bordeleau L., Meschino W.S. et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br. J. Cancer. 2019; 121(1): 15-21.https://dx.doi.org/10.1038/s41416-019-0446-1.
Schrijver L.H., Antoniou A.C., Olsson H., Mooij T.M., Roos-Blom M.J.,Azarang L. et al. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Am. J. Obstet. Gynecol. 2021; 225(1): 51.e1-51.e17. https://dx.doi.org/10.1016/j.ajog.2021.01.014.
Srour M.K., Amersi F., Mirocha J., Giuliano A.E., Chung A. Male breast cancer: 13-year single institution experience. Am. Surg. 2020; 86(10): 1345-50.https://dx.doi.org/10.1177/0003134820964444.
Hoffman A., Ben Ishay O., Horesh N., Shabtai M., Forschmidt E,. Rosin D. et al. Breast cancer in men: a single center experience over a period of 22 years. Isr. Med. Assoc. J. 2020; 22(3): 160-3.
Paluch-Shimon S., Cardoso F., Sessa C., Balmana J., Cardoso M.J.,Gilbert F., Senkus E.; ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann. Oncol. 2016; 27(Suppl. 5): v103-10. https://dx.doi.org/10.1093/annonc/mdw327.

Received 23.06.2022

Accepted 26.08.2022

Svetlana V. Yureneva, Dr. Med. Sci., Professor at the Department of Obstetrics and Gynecology of the Department of Vocational Education, Leading Researcher at the Department of Gynecological Endocrinology, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology,
Ministry of Health of Russia, +7(916)179-74-00, syureneva@gmail.com, https://doi.org/0000-0003-2864-066Х, 117997, Russia, Moscow, Ac. Oparin str., 4.
Marina V. Averyanova, Ph.D. student at the Department of Gynecological Endocrinology, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, +7(968)979-23-97, marisha199022@mail.ru, https://orcid.org/0000-0002-2995-5228,
117997, Russia, Moscow, Ac. Oparin str., 4.
Lev A. Ashrafyan, Academician of RAS, Dr. Med. Sci., Professor, Director of the Institute of Oncology and Mammology, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, levaa2004@yahoo.com, https://orcid.org/0000-0001-6396-4948,
117997, Russia, Moscow, Ac. Oparin str., 4.
Oksana V. Yakushevskaya, PhD, obstetrician-gynecologist, Researcher at the Department of Gynecological Endocrinology, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, +7(495)531-44-44, aluckyone777@gmail.com, https://orcid.org/0002-7430-1207,
117997, Russia, Moscow, Ac. Oparin str., 4.
Olga A. Buyanovskaya, PhD, clinical genetics at the Department of Clinical Genetics, of Reproductive Genetics, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, o_duyanovskaya@oparina4.ru, https://orcid.org/0000-0001-6622-6430,
117997, Russia, Moscow, Ac. Oparin str., 4.

Authors’ contributions: Yureneva S.V., Ashrafyan L.A., Averyanova M.V., Yakushevskaya O.V. – concept, development of the design of the article; analysis of scientific material; Averyanova M.V. – material collection and processing; writing the text;
Yureneva S.V., Ashrafyan L.A., Yakushevskaya O.V., Buyanovskaya O.A. – editing; All the authors have made an equal contribution to the preparation of the publication.
Conflicts of interest: The authors declare that there are no conflicts of interest.
Funding: The article has been prepared without sponsorship.
For citation: Yureneva S.V., Averyanova M.V., Ashrafyan L.A., Yakushevskaya O.V., Buyanovskaya O.A. Pathogenic variants in the BRCA 1 and BRCA2 genes:
what is important for a practicing gynecologist to know.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2022; 11: 52-59 (in Russian)
https://dx.doi.org/10.18565/aig.2022.11.52-59

Pathogenic variants in the BRCA 1 and BRCA2 genes: what is important for a practicing gynecologist to know

Yureneva S.V., Averyanova M.V., Ashrafyan L.A., Yakushevskaya O.V., Buyanovskaya O.A.

Keywords

References

About the Authors

Similar Articles